{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:38:46Z","timestamp":1788928726003,"version":"build-2803163510"},"reference-count":36,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,26]],"date-time":"2021-12-26T00:00:00Z","timestamp":1640476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The extent of SARS-CoV-2 infection among a population may be assessed by the presence of serum SARS-CoV-2 antibodies, which indicates previous exposure. The aim of this study was to determine the seroprevalence of SARS-CoV-2 infection in the adult population from Western Romania. Materials and Methods: Samples of 2443 consecutive individuals, referred for routine laboratory investigations, were tested for SARS-CoV-2 antibodies using the Elecsys immunoassay that targets the nucleocapsid protein, for identifying the presence of the total antibodies against SARS-CoV-2. Results: The overall SARS-CoV-2 seroprevalence was 45.60%. SARS-CoV-2 seroprevalence was significantly higher in age group 30\u201349 years (53.94%) compared to age groups 50\u201369 years (43.53%) and 70\u201391 years (30.79%) (p &lt; 0.001, p &lt; 0.001, respectively). No significant difference in seroprevalence was observed between females (44.83%) and males (47.05%). Conclusions: Our data revealed a high seroprevalence of SARS-CoV-2 infection in the adult population from Western Romania and indicate the rapid and significant spread of the virus. The estimated prevalence of 45.60% was 6 times higher than the rate of confirmed COVID-19 cases reported in the study area. This indicates the magnitude of virus transmission in the community.<\/jats:p>","DOI":"10.3390\/medicina58010035","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T01:06:54Z","timestamp":1640567214000},"page":"35","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["SARS-CoV-2 Seroprevalence in Western Romania, March to June 2021"],"prefix":"10.3390","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-3729","authenticated-orcid":false,"given":"Tudor Rares","family":"Olariu","sequence":"first","affiliation":[{"name":"Discipline of Parasitology, Department of Infectious Disease, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Clinical Laboratory, Municipal Clinical Emergency Teaching Hospital, 300254 Timisoara, Romania"},{"name":"Center for Diagnosis and Study of Parasitic Diseases, Department of Infectious Disease, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Cristiana","family":"Craciun","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Municipal Clinical Emergency Teaching Hospital, 300254 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daliborca Cristina","family":"Vlad","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Pharmacology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Clinical Laboratory, County Clinical Emergency Teaching Hospital, 300723 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Dumitrascu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Pharmacology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Clinical Laboratory, County Clinical Emergency Teaching Hospital, 300723 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iosif","family":"Marincu","sequence":"additional","affiliation":[{"name":"Discipline of Parasitology, Department of Infectious Disease, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-1934","authenticated-orcid":false,"given":"Maria Alina","family":"Lupu","sequence":"additional","affiliation":[{"name":"Discipline of Parasitology, Department of Infectious Disease, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Center for Diagnosis and Study of Parasitic Diseases, Department of Infectious Disease, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Clinical Laboratory, Institute of Cardiovascular Diseases, 300310 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jinf.2020.05.067","article-title":"High SARS-CoV-2 Antibody prevalence among healthcare workers exposed to COVID-19 patients","volume":"81","author":"Chen","year":"2020","journal-title":"J. Infect."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(20)31483-5","article-title":"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A nationwide, population-based seroepidemiological study","volume":"396","author":"Oteo","year":"2020","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)31482-3","article-title":"SARS-CoV-2 seroprevalence in COVID-19 hotspots","volume":"396","author":"Eckerle","year":"2020","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S1473-3099(21)00054-2","article-title":"Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak","volume":"21","author":"Stringhini","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Vilibic-Cavlek, T., Stevanovic, V., Ilic, M., Barbic, L., Capak, K., Tabain, I., Jasna Krleza, L., Ferenc, T., Hruskar, Z., and Topic, R.Z. (2021). SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia. Pathogens, 10.","DOI":"10.3390\/pathogens10060774"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Byambasuren, O., Dobler, C.C., Bell, K., Rojas, D.P., Clark, J., McLaws, M.L., and Glasziou, P. (2021). Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0248946"},{"key":"ref_8","first-page":"e925","article-title":"Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: A population-based study","volume":"97","author":"Calampa","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_9","unstructured":"European Centre for Disease Prevention and Control (2021, December 19). COVID-19 Situation Update for the EU\/EEA. Available online: https:\/\/www.ecdc.europa.eu\/en\/cases-2019-ncov-eueea."},{"key":"ref_10","unstructured":"Timis Department of Public Health (2021, December 19). Direc\u0163ia de S\u0103n\u0103tate Public\u0103 Timi\u015f, Ministerul S\u0103n\u0103t\u0103\u0163ii. (In Romanian)."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.18683\/germs.2020.1198","article-title":"SARS-CoV-2 in Romania\u2014Analysis of the first confirmed case and evolution of the pandemic in Romania in the first three months","volume":"10","author":"Apostolescu","year":"2020","journal-title":"Germs"},{"key":"ref_12","unstructured":"European Union Agency for Fundamental Rights (FRA) (2021, November 20). Coronavirus Pandemic in the EU\u2014Fundamental Rights Implications. Country: Romania. Available online: https:\/\/fra.europa.eu\/sites\/default\/files\/fra_uploads\/ro_report_on_coronavirus_pandemic_june_2020.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cmi.2020.12.027","article-title":"Seroprevalence of SARS-CoV-2 antibodies in 2115 blood donors from Romania","volume":"27","author":"Olariu","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMc2102051","article-title":"Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine","volume":"384","author":"Bradley","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"104962","DOI":"10.1016\/j.jcv.2021.104962","article-title":"Evaluation of the immune response to COVID-19 vaccine mRNA BNT162b2 and correlation with previous COVID-19 infection","volume":"143","author":"Bongiovanni","year":"2021","journal-title":"J. Clin. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cca.2021.03.007","article-title":"Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2 in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological cassays from the same manufacturer","volume":"518","author":"Mueller","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2123622","DOI":"10.1001\/jamanetworkopen.2021.23622","article-title":"Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis","volume":"1","author":"Yau","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1039.e1","DOI":"10.1016\/j.cmi.2021.03.009","article-title":"Seroprevalence of severe acute respiratory syndrome coronavirus 2 in Slovenia: Results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned","volume":"27","author":"Poljak","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1038\/s41598-021-82662-x","article-title":"Estimated seroprevalence of SARS-CoV-2 antibodies among adults in Orange County, California","volume":"11","author":"Bruckner","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.cmi.2020.10.020","article-title":"SARS-CoV-2 seroprevalence worldwide: A systematic review and meta-analysis","volume":"27","author":"Rostami","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e64206","DOI":"10.7554\/eLife.64206","article-title":"Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys","volume":"10","author":"Larremore","year":"2021","journal-title":"eLife"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Bobrovitz, N., Arora, R.K., Cao, C., Boucher, E., Liu, M., Donnici, C., Yanes-Lane, M., Whelan, M., Perlman-Arrow, S., and Chen, J. (2021). Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0252617"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gegout Petit, A., Jeulin, H., Legrand, K., Jay, N., Bochnakian, A., Vallois, P., Schvoerer, E., and Guillemin, F. (2021). Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France. Viruses, 13.","DOI":"10.3390\/v13061076"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100148","DOI":"10.1016\/j.lanepe.2021.100148","article-title":"Exposures associated with SARS-CoV-2 infection in France: A nationwide online case-control study","volume":"7","author":"Galmiche","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Napolitano, F., Di Giuseppe, G., Montemurro, M.V., Molinari, A.M., Donnarumma, G., Arnese, A., Pavia, M., and Angelillo, I.F. (2021). Seroprevalence of SARS-CoV-2 Antibodies in Adults and Healthcare Workers in Southern Italy. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18094761"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.annepidem.2021.04.007","article-title":"Dynamics of the COVID-19 epidemic in urban and rural areas in the United States","volume":"59","author":"Cuadros","year":"2021","journal-title":"Ann. Epidemiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/jrh.12486","article-title":"Progression of COVID-19 From Urban to Rural Areas in the United States: A Spatiotemporal Analysis of Prevalence Rates","volume":"36","author":"Paul","year":"2020","journal-title":"J. Rural Health"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Chisale, M.R.O., Ramazanu, S., Mwale, S.E., Kumwenda, P., Chipeta, M., Kaminga, A.C., Nkhata, O., Nyambalo, B., Chavura, E., and Mbakaya, B.C. (2021). Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis. Rev. Med. Virol., e2271.","DOI":"10.1002\/rmv.2271"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1080\/22221751.2020.1787799","article-title":"Risk factors associated with COVID-19 infection: A retrospective cohort study based on contacts tracing","volume":"9","author":"Liu","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Dattner, I., Goldberg, Y., Katriel, G., Yaari, R., Gal, N., Miron, Y., Ziv, A., Sheffer, R., Hamo, Y., and Huppert, A. (2021). The role of children in the spread of COVID-19: Using household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children. PLoS Comput. Biol., 17.","DOI":"10.1371\/journal.pcbi.1008559"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"13903","DOI":"10.1038\/s41598-021-92500-9","article-title":"Children\u2019s role in the COVID-19 pandemic: A systematic review of early surveillance data on susceptibility, severity, and transmissibility","volume":"11","author":"Gaythorpe","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamainternmed.2020.7976","article-title":"Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020","volume":"181","author":"Bajema","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/S2468-2667(21)00064-5","article-title":"Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: A modelling study","volume":"6","author":"Paireau","year":"2021","journal-title":"Lancet Public Health"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.2020008367","article-title":"Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset","volume":"136","author":"Perreault","year":"2020","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103256","DOI":"10.1016\/j.transci.2021.103256","article-title":"Sero-prevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Norway, winter\/spring 2021","volume":"60","author":"Hvalryg","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_36","unstructured":"European Centre for Disease Prevention and Control (2021, November 09). SARS-COV-2 Delta Variant Now Dominant in Much of the European Region and Efforts Must be Reinforced to Prevent Transmission, Warn WHO\/Europe and ECDC. Available online: https:\/\/www.ecdc.europa.eu\/en\/news-events\/sars-cov-2-delta-variant-now-dominant-european-region."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/1\/35\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:53:36Z","timestamp":1760169216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/1\/35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,26]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["medicina58010035"],"URL":"https:\/\/doi.org\/10.3390\/medicina58010035","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,26]]}}}